Stock SNY SANOFI
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sanofi Nasdaq

Equities

SNY

US80105N1054

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 11:32:04 2024-07-12 am EDT 		5-day change 1st Jan Change
51.62 USD +0.79% Intraday chart for Sanofi +3.89% +3.74%
05:20pm Banks Including Goldman Sachs, Morgan Stanley Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale, Bloomberg Reports MT
Jul. 10 US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 112,310 98,877 111,194 112,665 112,549 117,273 - -
Enterprise Value (EV) 1 128,816 107,666 121,177 119,102 120,342 124,610 120,245 114,984
P/E ratio 40 x 8.01 x 17.8 x 16.7 x 20.8 x 16.9 x 13.8 x 12.3 x
Yield 3.51% 4.07% 3.76% 3.96% 4.19% 4.12% 4.33% 4.74%
Capitalization / Revenue 3.11 x 2.74 x 2.94 x 2.62 x 2.61 x 2.52 x 2.35 x 2.22 x
EV / Revenue 3.57 x 2.99 x 3.21 x 2.77 x 2.79 x 2.68 x 2.41 x 2.18 x
EV / EBITDA 10.8 x 9.41 x 9.95 x 8.14 x 8.44 x 9.11 x 7.75 x 6.91 x
EV / FCF 21.7 x 15.4 x 15 x 14 x 14.2 x 17.2 x 12.7 x 11 x
FCF Yield 4.6% 6.48% 6.68% 7.12% 7.04% 5.81% 7.88% 9.12%
Price to Book 1.9 x 1.57 x 1.62 x 1.5 x 1.52 x 1.52 x 1.43 x 1.35 x
Nbr of stocks (in thousands) 1,253,178 1,256,375 1,255,293 1,254,060 1,253,891 1,250,117 - -
Reference price 2 89.62 78.70 88.58 89.84 89.76 93.81 93.81 93.81
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/1/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 36,126 36,041 37,761 42,997 43,070 46,540 49,824 52,771
EBITDA 1 11,904 11,443 12,183 14,627 14,259 13,682 15,518 16,651
EBIT 1 9,758 9,762 10,714 13,040 12,670 12,103 13,906 15,146
Operating Margin 27.01% 27.09% 28.37% 30.33% 29.42% 26.01% 27.91% 28.7%
Earnings before Tax (EBT) 1 2,822 13,804 7,798 8,268 7,038 8,886 11,386 12,745
Net income 1 2,806 12,314 6,223 6,720 5,400 7,037 8,527 9,502
Net margin 7.77% 34.17% 16.48% 15.63% 12.54% 15.12% 17.11% 18.01%
EPS 2 2.240 9.820 4.970 5.370 4.310 5.555 6.797 7.656
Free Cash Flow 1 5,928 6,982 8,096 8,483 8,478 7,245 9,476 10,485
FCF margin 16.41% 19.37% 21.44% 19.73% 19.68% 15.57% 19.02% 19.87%
FCF Conversion (EBITDA) 49.8% 61.02% 66.45% 58% 59.46% 52.95% 61.07% 62.96%
FCF Conversion (Net income) 211.26% 56.7% 130.1% 126.24% 157% 102.95% 111.13% 110.34%
Dividend per Share 2 3.150 3.200 3.330 3.560 3.760 3.862 4.063 4.448
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/1/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 10,432 9,994 9,674 10,116 12,482 10,725 10,222 9,965 11,964 10,919 10,464 10,390 12,961 11,868 10,805
EBITDA 1 3,952 2,623 3,426 3,163 4,931 3,107 3,703 3,087 4,460 3,009 3,192 2,780 4,389 2,618 -
EBIT 1 3,558 2,256 3,065 2,753 4,498 2,724 3,333 2,726 4,028 2,583 2,843 2,662 4,211 2,629 3,045
Operating Margin 34.11% 22.57% 31.68% 27.21% 36.04% 25.4% 32.61% 27.36% 33.67% 23.66% 27.17% 25.62% 32.49% 22.15% 28.18%
Earnings before Tax (EBT) 1 2,957 1,391 2,349 1,383 2,666 1,921 2,468 1,718 2,971 -249 1,310 2,011 3,684 2,137 -
Net income 1 2,317 1,131 2,009 1,175 2,076 1,460 1,995 1,435 2,525 -555 1,133 1,539 2,824 1,587 -
Net margin 22.21% 11.32% 20.77% 11.62% 16.63% 13.61% 19.52% 14.4% 21.1% -5.08% 10.83% 14.81% 21.79% 13.37% -
EPS 2 1.850 0.9000 1.610 0.9400 1.660 1.160 1.600 1.150 2.010 -0.4400 0.9100 1.226 2.241 1.258 -
Dividend per Share 2 - 3.330 - - - 3.560 - - - 3.760 0.9292 0.9424 0.9424 0.9424 1.003
Announcement Date 10/28/21 2/4/22 4/28/22 7/28/22 10/28/22 2/3/23 4/27/23 7/28/23 10/27/23 2/1/24 4/25/24 - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 16,506 8,789 9,983 6,437 7,793 7,336 2,971 -
Net Cash position 1 - - - - - - - 2,289
Leverage (Debt/EBITDA) 1.387 x 0.7681 x 0.8194 x 0.4401 x 0.5465 x 0.5362 x 0.1915 x -
Free Cash Flow 1 5,928 6,982 8,096 8,483 8,478 7,245 9,476 10,485
ROE (net income / shareholders' equity) 12.7% 12.1% 12.5% 14.4% 13.6% 12.2% 13.5% 13.9%
ROA (Net income/ Total Assets) 2.5% 6.47% 5.3% 8.37% 4.27% 6.33% 7.15% 7.39%
Assets 1 112,072 190,442 117,327 80,248 126,517 111,171 119,243 128,591
Book Value Per Share 2 47.20 50.30 54.80 59.70 59.20 61.90 65.50 69.30
Cash Flow per Share 2 6.160 5.940 8.360 8.410 8.200 8.040 9.380 10.80
Capex 1 1,816 1,329 2,043 2,201 3,024 2,058 2,405 2,509
Capex / Sales 5.03% 3.69% 5.41% 5.12% 7.02% 4.42% 4.83% 4.76%
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/1/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
93.81 EUR
Average target price
108.8 EUR
Spread / Average Target
+16.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.16% 841B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 625B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.46% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.78% 327B
ABBVIE INC. Stock AbbVie Inc.
+10.47% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.75% 242B
NOVARTIS AG Stock Novartis AG
+17.92% 227B
AMGEN INC. Stock Amgen Inc.
+14.97% 174B
PFIZER, INC. Stock Pfizer, Inc.
+0.64% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. SNY Stock
  5. Financials Sanofi